Track record

​The Department of Oncology at the Finsen Center has been running early clinical trials for more than 25 years. Since 2005, we have had an up-to-date dedicated Phase I Unit, with cardiac monitoring, and laboratory facilities with possibilities of immediate handling of blood samples and biopsies.

Our track record include early trials of gemcitabine and taxanes and other anti-neoplastic agents in collaboration with EORTC Early Clinical Trials Group. We have experience with cytotoxic drugs, anti-angiogenic and EGFR agents, anti-hormonal agents, diagnostic agents, immunooncology, immunotoxins, therapeutic and imaging antibodies and drug resistance modifiers.

We have experience with several FIH studies, including 11 ongoing, and a total of 20-25 ongoing Phase 1 studies.

Responsible editor